Tuning mPEG-PLA/vitamin E-TPGS-based mixed micelles for combined celecoxib/honokiol therapy for breast cancer
作者: Jiahui SunJing LiQi LiuMin JiangMengjia YangSiwen ZhanTong QiuKaiyong HeXueqiong Zhang
作者单位: 1Department of Pharmaceutical Engineering , School of Chemical Engineering, Wuhan University of Technology , Wuhan 430070 , PR China
2State Key Laboratory of Advanced Technology for Materials Synthesis and Processing , Wuhan University of Technology , Wuhan 430070 , PR China
3Department of Dermatology , Johns Hopkins University School of Medicine , Baltimore , Maryland , 21231 , USA
4Biomedical Materials and Engineering Center , Wuhan University of Technology , Wuhan 430070 , PR China
5Hubei Institute for Drug Control , Wuhan 430070 , PR China
刊名: European Journal of Pharmaceutical Sciences, 2020, Vol.146
来源数据库: Elsevier Journal
DOI: 10.1016/j.ejps.2020.105277
关键词: Breast cancerCelecoxibHonokiolMixed micellesCombined treatmentSynergistic effect
原始语种摘要: Abstract(#br)This study aimed to develop, evaluate, and optimize the mPEG-PLA/vitamin E-TPGS mixed micelle drug delivery system to encapsulate celecoxib (CXB) and honokiol (HNK) for intravenous treatment of breast cancer. To this end, we formulated CXB-loaded mPEG-PLA/vitamin E-TPGS (PV-CXB) and HNK-loaded mPEG-PLA/vitamin E-TPGS (PV-HNK) mixed micelles and analyzed their characteristics. The 4T1 cell line was used for cytotoxicity determination and cellular uptake experiments, and for establishing a 4T1-bearing mouse model for histopathology, immunofluorescence, terminal deoxynucleotidyl transferase-mediated nick end labeling, and Western blot analysis. The synergistic effects of PV-CXB and PV-HNK combination therapy were investigated in vitro and in vivo using the coefficient of drug...
全文获取路径: Elsevier  (合作)
影响因子:2.987 (2012)

  • combined 组合
  • breast 胸部
  • vitamin 维生素
  • cancer 癌症
  • PLA phase alternating line
  • therapy 治疗
  • cytotoxicity 细胞毒性
  • combination 聚形
  • histopathology 组织病理学
  • mixed 混合的